Tarsus Company Profile
What is the competitive landscape for TARSUS
TARSUS has one approved drug.
There are nine US patents protecting TARSUS drugs.
Drugs and US Patents for Tarsus
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tarsus | XDEMVY | lotilaner | SOLUTION/DROPS;OPHTHALMIC | 217603-001 | Jul 24, 2023 | RX | Yes | Yes | 10,835,517 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Tarsus | XDEMVY | lotilaner | SOLUTION/DROPS;OPHTHALMIC | 217603-001 | Jul 24, 2023 | RX | Yes | Yes | 11,690,826 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Tarsus | XDEMVY | lotilaner | SOLUTION/DROPS;OPHTHALMIC | 217603-001 | Jul 24, 2023 | RX | Yes | Yes | 11,752,137 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Tarsus | XDEMVY | lotilaner | SOLUTION/DROPS;OPHTHALMIC | 217603-001 | Jul 24, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Tarsus | XDEMVY | lotilaner | SOLUTION/DROPS;OPHTHALMIC | 217603-001 | Jul 24, 2023 | RX | Yes | Yes | 8,383,659 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Tarsus | XDEMVY | lotilaner | SOLUTION/DROPS;OPHTHALMIC | 217603-001 | Jul 24, 2023 | RX | Yes | Yes | 12,213,964 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Tarsus Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Israel | 275339 | ⤷ Start Trial |
| Brazil | PI0923009 | ⤷ Start Trial |
| Japan | 2021506971 | ⤷ Start Trial |
| Hungary | E067461 | ⤷ Start Trial |
| Canada | 3085787 | ⤷ Start Trial |
| Denmark | 3723739 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Tarsus Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2379537 | 132017000099235 | Italy | ⤷ Start Trial | PRODUCT NAME: LOTILANER(CREDELIO); AUTHORISATION NUMBER(S) AND DATE(S): EU/2/17/206, 20170427 |
| 2379537 | LUC00030 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: LOTILANER ET SES SELS; AUTHORISATION NUMBER AND DATE: EU/2/17/206 20170427 |
| 2379537 | 300891 | Netherlands | ⤷ Start Trial | PRODUCT NAME: LOTILANER EN ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/2/17/206 20170427 |
| 2379537 | 122017000053 | Germany | ⤷ Start Trial | PRODUCT NAME: LOTILANER; REGISTRATION NO/DATE: EU/2/17/206 20170425 |
| 2379537 | 2017/037 | Ireland | ⤷ Start Trial | PRODUCT NAME: LOTILANER AND SALTS THEREOF.; REGISTRATION NO/DATE: EU/2/17/206 20170425 |
| 2379537 | 40/2017 | Austria | ⤷ Start Trial | PRODUCT NAME: LOTILANER UND SALZE DAVON; REGISTRATION NO/DATE: EU/2/17/206 (MITTEILUNG) 20170427 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.

